Acute Lung Injury: Epidemiology, Health Effects and Therapeutic Treatment Strategies

Daniela Mokrá, MD, PhD (Editor)
Biomedical Center Martin and Department of Physiology Comenius University in Bratislava Jessenius, Faculty of Medicine in Martin, Slovakia

Series: Pulmonary and Respiratory Diseases and Disorders
BISAC: MED079000



Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick


Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:



In this book, authors review the current knowledge on acute lung injury (ALI). ALI/acute respiratory distress syndrome (ARDS) is characterized by diffuse alveolar damage, alveolar capillary leakage, lung edema, neutrophil-derived inflammation, and surfactant dysfunction. These changes lead to clinical manifestations of decreased lung compliance, severe hypoxemia, and bilateral pulmonary infiltrates.

In the first chapter the authors describe how two different models of multi-causality (intuitively appealing threshold model and abstract sufficient cause model), both of which are commonly used in the description of the etiology of diseases, can be applied to transfusion related acute lung injury (TRALI) and can both be used to describe the same observed relations between multiple risk factors and TRALI. In the second chapter, a dysfunction of the normal endothelial–epithelial barriers and its role in the development of acute lung injury is described. Two leading pathogenic mechanisms of ALI are increased endothelial permeability and reduced alveolar liquid clearance capacity. Understanding of the fundamental mechanisms involved in the regulation of endothelial permeability is essential for the development of barrier protective therapeutic strategies.

The following two chapters are focused on novel therapeutic strategies used in the treatment of ALI and more severe form acute respiratory distress syndrome (ARDS). Appropriate treatment involves protective lung ventilation, optimal fluid management, and pharmacological treatment. Despite that there are several possibilities of potentially beneficial pharmacotherapy of ALI/ARDS, the results of experimental and clinical studies are often controversial. The authors review the use of various pharmacological agents (including corticosteroids, neutrophil elastase inhibitors, anticoagulants, pulmonary vasodilators, antioxidants, methylxanthines, exogenous surfactant, gene-therapy, cell therapy, nitric oxide, myorelaxants, beta-agonists) and critically evaluate their effects in animal models and in patients with ALI/ARDS. (Imprint: Nova Biomedical)


Chapter 1 - TRALI Not a Two Hit, But a Multi-Causal Model (pp. 1-18)
Rutger A. Middelburg and Johanna G. van der Bom (Center for Clinical Transfusion Research, Sanquin Research, Leiden; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands)

Chapter 2 - Mechanisms and Prevention of Pulmonary Microvascular Hyperpermeability in Acute Lung Injury (pp. 19-36)
Qiang Zhao, Qin Liu and Jinzhou Zhang (Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, China and others)

Chapter 3 - Pharmacological Therapies for Acute Respiratory Distress Syndrome (pp. 37-44)
Hironobu Hamada (Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan)

Chapter 4 - Novel Trends in Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome (pp. 45-76)
Daniela Mokrá and Juraj Mokry (Department of Physiology, Department of Pharmacology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Martin, Slovakia, EU)

Editor Contact Information


You have not viewed any product yet.